Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Steven Coultrap and Karl Bayer.

 
Connection Strength
 
 
 
6.641
 
  1. Coultrap SJ, Zaegel V, Bayer KU. CaMKII isoforms differ in their specific requirements for regulation by nitric oxide. FEBS Lett. 2014 Dec 20; 588(24):4672-6.
    View in: PubMed
    Score: 0.565
  2. Coultrap SJ, Bayer KU. Nitric oxide induces Ca2+-independent activity of the Ca2+/calmodulin-dependent protein kinase II (CaMKII). J Biol Chem. 2014 Jul 11; 289(28):19458-65.
    View in: PubMed
    Score: 0.547
  3. Coultrap SJ, Freund RK, O'Leary H, Sanderson JL, Roche KW, Dell'Acqua ML, Bayer KU. Autonomous CaMKII mediates both LTP and LTD using a mechanism for differential substrate site selection. Cell Rep. 2014 Feb 13; 6(3):431-7.
    View in: PubMed
    Score: 0.536
  4. Coultrap SJ, Bayer KU. CaMKII regulation in information processing and storage. Trends Neurosci. 2012 Oct; 35(10):607-18.
    View in: PubMed
    Score: 0.479
  5. Coultrap SJ, Barcomb K, Bayer KU. A significant but rather mild contribution of T286 autophosphorylation to Ca2+/CaM-stimulated CaMKII activity. PLoS One. 2012; 7(5):e37176.
    View in: PubMed
    Score: 0.476
  6. Coultrap SJ, Bayer KU. Improving a natural CaMKII inhibitor by random and rational design. PLoS One. 2011; 6(10):e25245.
    View in: PubMed
    Score: 0.456
  7. Coultrap SJ, Vest RS, Ashpole NM, Hudmon A, Bayer KU. CaMKII in cerebral ischemia. Acta Pharmacol Sin. 2011 Jul; 32(7):861-72.
    View in: PubMed
    Score: 0.447
  8. Coultrap SJ, Buard I, Kulbe JR, Dell'Acqua ML, Bayer KU. CaMKII autonomy is substrate-dependent and further stimulated by Ca2+/calmodulin. J Biol Chem. 2010 Jun 04; 285(23):17930-7.
    View in: PubMed
    Score: 0.410
  9. Brown CN, Rumian NL, Tullis JE, Coultrap SJ, Bayer KU. Aß-induced synaptic impairments require CaMKII activity that is stimulated by indirect signaling events. iScience. 2022 Jun 17; 25(6):104368.
    View in: PubMed
    Score: 0.237
  10. Tullis JE, Buonarati OR, Coultrap SJ, Bourke AM, Tiemeier EL, Kennedy MJ, Herson PS, Bayer KU. GluN2B S1303 phosphorylation by CaMKII or DAPK1: no indication for involvement in ischemia or LTP. iScience. 2021 Oct 22; 24(10):103214.
    View in: PubMed
    Score: 0.228
  11. Brown CN, Cook SG, Allen HF, Crosby KC, Singh T, Coultrap SJ, Bayer KU. Characterization of six CaMKIIa variants found in patients with schizophrenia. iScience. 2021 Oct 22; 24(10):103184.
    View in: PubMed
    Score: 0.228
  12. Cook SG, Buonarati OR, Coultrap SJ, Bayer KU. CaMKII holoenzyme mechanisms that govern the LTP versus LTD decision. Sci Adv. 2021 04; 7(16).
    View in: PubMed
    Score: 0.221
  13. Buonarati OR, Cook SG, Goodell DJ, Chalmers NE, Rumian NL, Tullis JE, Restrepo S, Coultrap SJ, Quillinan N, Herson PS, Bayer KU. CaMKII versus DAPK1 Binding to GluN2B in Ischemic Neuronal Cell Death after Resuscitation from Cardiac Arrest. Cell Rep. 2020 01 07; 30(1):1-8.e4.
    View in: PubMed
    Score: 0.202
  14. Cook SG, Bourke AM, O'Leary H, Zaegel V, Lasda E, Mize-Berge J, Quillinan N, Tucker CL, Coultrap SJ, Herson PS, Bayer KU. Analysis of the CaMKIIa and ß splice-variant distribution among brain regions reveals isoform-specific differences in holoenzyme formation. Sci Rep. 2018 04 03; 8(1):5448.
    View in: PubMed
    Score: 0.179
  15. Woolfrey KM, O'Leary H, Goodell DJ, Robertson HR, Horne EA, Coultrap SJ, Dell'Acqua ML, Bayer KU. CaMKII regulates the depalmitoylation and synaptic removal of the scaffold protein AKAP79/150 to mediate structural long-term depression. J Biol Chem. 2018 02 02; 293(5):1551-1567.
    View in: PubMed
    Score: 0.175
  16. Goodell DJ, Zaegel V, Coultrap SJ, Hell JW, Bayer KU. DAPK1 Mediates LTD by Making CaMKII/GluN2B Binding LTP Specific. Cell Rep. 2017 06 13; 19(11):2231-2243.
    View in: PubMed
    Score: 0.169
  17. Barcomb K, Buard I, Coultrap SJ, Kulbe JR, O'Leary H, Benke TA, Bayer KU. Autonomous CaMKII requires further stimulation by Ca2+/calmodulin for enhancing synaptic strength. FASEB J. 2014 Aug; 28(8):3810-9.
    View in: PubMed
    Score: 0.137
  18. Goodell DJ, Eliseeva TA, Coultrap SJ, Bayer KU. CaMKII binding to GluN2B is differentially affected by macromolecular crowding reagents. PLoS One. 2014; 9(5):e96522.
    View in: PubMed
    Score: 0.136
  19. Kulbe JR, Mulcahy Levy JM, Coultrap SJ, Thorburn A, Bayer KU. Excitotoxic glutamate insults block autophagic flux in hippocampal neurons. Brain Res. 2014 Jan 13; 1542:12-9.
    View in: PubMed
    Score: 0.133
  20. Barcomb K, Coultrap SJ, Bayer KU. Enzymatic activity of CaMKII is not required for its interaction with the glutamate receptor subunit GluN2B. Mol Pharmacol. 2013 Dec; 84(6):834-43.
    View in: PubMed
    Score: 0.131
  21. O'Leary H, Liu WH, Rorabaugh JM, Coultrap SJ, Bayer KU. Nucleotides and phosphorylation bi-directionally modulate Ca2+/calmodulin-dependent protein kinase II (CaMKII) binding to the N-methyl-D-aspartate (NMDA) receptor subunit GluN2B. J Biol Chem. 2011 Sep 09; 286(36):31272-81.
    View in: PubMed
    Score: 0.112
  22. Buard I, Coultrap SJ, Freund RK, Lee YS, Dell'Acqua ML, Silva AJ, Bayer KU. CaMKII "autonomy" is required for initiating but not for maintaining neuronal long-term information storage. J Neurosci. 2010 Jun 16; 30(24):8214-20.
    View in: PubMed
    Score: 0.104
  23. Vest RS, O'Leary H, Coultrap SJ, Kindy MS, Bayer KU. Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor. J Biol Chem. 2010 Jul 02; 285(27):20675-82.
    View in: PubMed
    Score: 0.103
  24. Buonarati OR, Miller AP, Coultrap SJ, Bayer KU, Reichow SL. Conserved and divergent features of neuronal CaMKII holoenzyme structure, function, and high-order assembly. Cell Rep. 2021 12 28; 37(13):110168.
    View in: PubMed
    Score: 0.058
  25. Opazo P, Viana da Silva S, Carta M, Breillat C, Coultrap SJ, Grillo-Bosch D, Sainlos M, Coussen F, Bayer KU, Mulle C, Choquet D. CaMKII Metaplasticity Drives Aß Oligomer-Mediated Synaptotoxicity. Cell Rep. 2018 06 12; 23(11):3137-3145.
    View in: PubMed
    Score: 0.045
  26. Myers JB, Zaegel V, Coultrap SJ, Miller AP, Bayer KU, Reichow SL. Publisher Correction: The CaMKII holoenzyme structure in activation-competent conformations. Nat Commun. 2018 05 25; 9:16180.
    View in: PubMed
    Score: 0.045
  27. Myers JB, Zaegel V, Coultrap SJ, Miller AP, Bayer KU, Reichow SL. The CaMKII holoenzyme structure in activation-competent conformations. Nat Commun. 2017 06 07; 8:15742.
    View in: PubMed
    Score: 0.042
  28. Deng G, Orfila JE, Dietz RM, Moreno-Garcia M, Rodgers KM, Coultrap SJ, Quillinan N, Traystman RJ, Bayer KU, Herson PS. Autonomous CaMKII Activity as a Drug Target for Histological and Functional Neuroprotection after Resuscitation from Cardiac Arrest. Cell Rep. 2017 01 31; 18(5):1109-1117.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2023 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)